Overview / Abstract: |
Patients with severe treatment-resistant asthma—estimated to account for 4%–10% of all asthma cases—are characterized by persistent symptoms, compromised lung function, and a significantly increased frequency and severity of high-risk outcomes. These patients are typically insensitive to corticosteroid treatment, except at very high doses—and are thus at greater risk for several serious diseases, including type 2 diabetes and osteoporosis. This elevated risk for morbidity underscores the need for corticosteroid-sparing alternative treatments. The discovery that severe asthma comprises at least two distinct phenotypes (eosinophilic and noneosinophilic) that are linked to differences in airway remodeling and inflammatory pathophysiology has potentially significant implications for managing this patient population. For patients with severe asthma driven by eosinophilic inflammation, several new tailored biologic therapies have received FDA approval (with others in the pipeline), offering viable therapeutic alternatives for these treatment-resistant patients. In this edition of RME Hot Seat, our expert faculty reviews the most recent evidence and provides answers to challenging clinical questions on the risks of asthma exacerbations, the newly available drugs for severe asthma, and current best practices for managing patients with severe asthma. |
Expiration |
Jun 30, 2018 |
Discipline(s) |
Nurse Practitioner , Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and RedMedEd. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Advanced practice nurses, nurses and physician assistants may participate in this educational activity and earn a letter of attendance as AANP, ANCC and AAPA accept AMA PRA Category 1 Credit(s)™ through their reciprocity agreements. |
Accreditation |
ACCME |
Is This Activity Certified for "Live" Credit? |
YES |
Presenters / Authors / Faculty |
Bradley E. Chipps, MD—Program Chair Stephen P. Peters, MD, PhD Michael E. Wechsler, MD, MMSc |
Activity Specialities / Related Topics |
Allergies / Allergic Reactions, Asthma, Education / Teaching, Family Medicine, Immunology / Immunosuppression, Internal Medicine, Primary Care, Pulmonary Medicine / COPD |
Sponsors / Supporters / Grant Providers |
Support for this activity has been provided through an educational grant from AstraZeneca. |
Keywords / Search Terms |
RedMedEd RedMedEd RedMedEd, RME Hot Seat, asthma, severe asthma, asthma treatment, treatment plans, assessment, patient management, Free CE, CME Free CE CME Live CE CME |